11-01 :: December 2010 / January 2011

nanotimes

Companies Facts

departments to form a Global Drug Discovery orga- nization. The expanded organization will be led by Bruce J. Sargent, Ph.D., newly appointed to senior vice president, drug discovery.

A

Under this reorganization, the company is combining its discovery chemistry and biology functions into a single unit across locations worldwide. Customers will better benefit from AMRI’s experience in per- forming fully coordinated multidisciplinary disco- very projects utilizing a global network of scientific experts, laboratories and equipment in medicinal chemistry, biology and/or ADMET. http://www.amriglobal.com

Nalamasu to Chief Technology Officer (CTO) for the Company, effective January 24, 2011. Dr. Nala- masu will report to chairman and CEO Mike Splinter and will provide critical insight to further enhance Applied’s technology leadership in the industries it serves.

A

2010 fourth quarter and year ended September 30, 2010. For the fiscal year ended September 30, 2010, Arrowhead reported revenues of $620,000, compa- red with $3.8 million for the fiscal year ended Sep- tember 30, 2009. Net loss attributable to Arrowhead for the 2010 fiscal year was $5.8 million, or $0.09 per share based on 64.3 million weighted average shares outstanding, compared with a net loss attri-

A http://www.appliedmaterials.com

rrowhead Research Corporation (NASDAQ: ARWR) announced financial results for its fiscal

pplied Materials, Inc. (NASDAQ: AMAT) an- nounced the promotion of Dr. Omkaram (Om)

MRI (NASDAQ: AMRI) announced the merging of its Discovery R&D and Discovery Chemistry

butable to Arrowhead of $19.3 million, or $0.43 per share based on 45.2 million weighted average shares outstanding in fiscal 2009. Full year operating ex- penses decreased by 60% from $23.3 million in fiscal 2009 to $9.4 million in fiscal 2010. The Company’s net cash used in operations for fiscal 2010 was $7.7 million, compared with $15.1 million in fiscal 2009. Cash provided by financing activities was $12.0 million, primarily due to proceeds from the issuan- ces of equity and warrants of $12.8 million offset by payments on capital lease obligation of $0.7 million. As of September 30, 2010, Arrowhead had cash and cash equivalents of $6.8 million and stockholders’ equity of $8.1 million. In 2010, 1. Arrowhead consolidated its ownership interest in Calando and simplified Calando’s capital structure through investment, conversion of debt, and acquisi- tion of minority interest.

2. Calando continued to enroll patients in its Phase I cancer trial and build relationships with potential partners and acquirers.

3. Unidym entered into IP cooperation and licensing agreements with Samsung Electronics generating revenue of $4.5 million in December 2010, allevi- ating Arrowhead of funding obligations for Unidym operations.

4. Nanotope entered into its first development partnership with Smith & Nephew, a global leader in medical technology, for up to $26.55 million in milestone payments plus potential sales royalties.

5. Arrowhead formed a new subsidiary, Ablaris Therapeutics, Inc., to commercialize obesity fighting therapeutics.

13